Kamal Hamed, Chief Medical Officer at Spero Therapeutics, Inc. (SPRO), sold 28,075 shares at $1.37 ($38K) on 2024-02-02, disclosed to the SEC on 2024-02-05.
Open-market sale of $38k SPRO by Chief Medical Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.